AcouSort AB (publ), a technology company, develops components and instruments used in the diagnostics, analytics, and cell therapy processing markets. It offers AcouTrap, a benchtop research instrument for sample preparation of cells, extracellular vesicles, bacteria, and viruses from various media; AcouPlasma, a module that enables in-line analysis of blood plasma from whole blood samples; Acoustic Separation Module, a microfluidic solution that provides continuous separation, washing or up-concentration of cells; Acoustic Trapping Module, a microfluidic cell sorters or quality control systems for bioreactors and cell therapy production; AQC Module, an in-line optical analysis of particle suspensions for quality control or monitoring applications; and AcouWash, a benchtop research instrument for label-free separation of target cells from various samples. The company has a collaboration agreement with Moeller Medical to exhibit a prototype system for analyzing separation of cells from body fluids. AcouSort AB (publ) was incorporated in 2010 and is based in Lund, Sweden.…
AcouSort (STO: ACOU) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 11 employees.
The shares were at 2.750 SEK on 20 November 2026, up 10.0% over 52 weeks. Its 52-week range is 2.030 SEK to 5.160 SEK: the price is 46.7% below the high and 35.5% above the low.
Its market capitalisation is 58.20M SEK.
AcouSort reports return on equity of -74.6%, an operating margin of -126.3% and revenue down 25.6% year over year.
It holds more cash than debt, a net cash position of 9.48M SEK. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. One analyst covers the stock; their mean price target of 9.000 SEK is 227.3% above the current price.
No upcoming events tracked.